Haemodynamics, fluids & transfusion
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial
An erratum to this article was published (Lancet, 1 Jul 2023 ↗)
Authors' conclusion
Among patients receiving a deceased donor kidney transplant, intravenous fluid therapy with balanced crystalloid solution reduced the incidence of DGF compared with saline.
Study context
- Population
- Adults and children receiving a deceased donor kidney transplant at 16 hospitals in Australia and New Zealand (excluding multi-organ transplant or weight <20 kg)
- Participants
- 404 vs 404
- Comparison
- Balanced crystalloid vs Saline
- Balanced crystalloidn = 404
- Salinen = 404reference
- Primary endpoint
- Delayed graft function (DGF), defined as receiving dialysis within 7 days after transplantation
- Follow-up
- 7 days
Methodological detailspragmatic, registry-embedded, multicentre, double-blind
- Pragmatic
- Registry-embedded
- Multicentre
- Double-blind
Primary result
As reported in the abstract
DGF
Each group vs salineAdjusted relative risk (95% CI)P value
Balanced crystalloid
0.74(0.66–0.84)
P < 0.0001Each group vs salineAdjusted risk difference (95% CI)
Balanced crystalloid
10.1%(3.5–16.6)
Safety
| Outcome | Balanced crystalloid | Saline | Adjusted risk difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Investigator-reported serious adverse events | <1% | 1% | −0.5% (−1.8 to 0.9) | P = 0.48 | |
| −2−101Difference (linear scale) |
- Investigator-reported serious adverse events: safety population: 406 vs 409
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial. Lancet. Published 18 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →